“ampyra” Archives

in
Entry Author Date Location
Acorda Gets FDA Nod for New Parkinson’s Drug, But Rival Looms 12/24/18 New York
Acorda’s Tough Week Continues as FDA Delays Parkinson’s Drug Review 09/13/18 New York
Bio Roundup: An Alzheimer’s Head-Scratcher, OUTBio, GSK & Gilead Shakeups   07/27/18 National
Activist Investor Scopia Gets Two Board Seats in Deal with Acorda 02/28/18 New York
Biotech Roundup: Obamacare Lite, DePinho Out, Dunsire In & More 03/10/17 National
Acorda Touts Success in Parkinson’s Drug Study, Awaits Safety Data 02/09/17 New York
Bio Roundup: CAR-T Ups & Downs, Lilly’s Failure, Myeloma & More 12/02/16 National
Acorda Leans on Parkinson’s Drugs After Post-Stroke Study Fails 11/21/16 New York
Four Years After Neuronex Buyout, Acorda Dumps Epilepsy Drug 05/20/16 New York
East Coast Bio Roundup: PCSK9 Battle, NYU Startups, Blueprint & More 03/17/16 Boston
East Coast Biotech Roundup: StartUp Health, Constellation, Highline & More 08/28/15 New York
East Coast Biotech Roundup: Forum, Crossovers, Immuno-Oncology & More 04/24/15 Boston
East Coast Biotech Roundup: Genzyme, 21st Century Cures, Acorda, & More 02/13/15 Boston
Alkermes Spinoff Civitas, Poised for IPO, Sells to Acorda for $525M 09/24/14 Boston
Alkermes CEO Richard Pops on Building Big, Playing Well with Pharma 04/18/14 Boston
Acorda Stock Climbs on Post-Stroke Study 04/15/13 New York
Five Questions: Acorda CEO Ron Cohen on the Future of Neurology R&D 04/17/12 New York
Allozyne Looks to Rustle Up Interest on Wall Street With Backdoor IPO 07/13/11 Seattle
Alkermes Acquires Elan Drug Manufacturing Unit for $960M 05/09/11 Boston
Acorda Issued Patent on MS Drug Following Days of Speculation 04/19/11 New York
Acorda Stock Halted as Shares Skyrocket on Patent Speculation 04/14/11 New York
Page 1 of 1